nivolumab
-
March 8, 2022
Immunotherapy Before Targeted Therapy Extends OS in Metastatic Melanoma Bookmark
George Lundberg, MDAs reported by Healio, immunotherapy followed by targeted therapy improved overall survival in a clinical trial with metastatic melanoma patients.
.
-
July 28, 2021
2021 ASCO Annual Meeting Bookmark
George Lundberg, MDResearchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.
.
-
July 14, 2021
What’s New in Melanoma Treatment in 2021?
Emma Shtivelman, PhDI last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Immune checkpoint inhibitors (ICI), antibody drugs that bind to proteins found on the immune system’s T cells—namely, PD-1 (which is targeted by the… Read more »
-
April 12, 2021
Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer Bookmark
George Lundberg, MDThe ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.
.
-
April 12, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Bookmark
George Lundberg, MDAn academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.
.
-
December 3, 2020
Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer Bookmark
George Lundberg, MDImmuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.
.
-
November 24, 2020
For Esophageal Cancer, Immunotherapy Likely to Play Larger Role Bookmark
George Lundberg, MDA blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer.
.
-
November 24, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Bookmark
George Lundberg, MDThis scientific research paper published in JAMA Oncology reports results from a clinical trial in which the drugs nivolumab and ipilimumab showed promising safety and efficacy for people with advanced liver cancer who had previously received the drug sorafenib.
.
-
August 15, 2020
ICI for Resected Stage IV Melanoma Bookmark
George Lundberg, MDResearch highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
In a clinical trial for metastatic melanoma patients, a combination of the drugs nivolumab and ipilimumab (both “immune checkpoint inhibitors,” or ICIs) outperformed nivolumab on its own, and nivolumab on its own outperformed a placebo.
Go to full research highlight published by Nature Reviews Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.